Safe transition to biosimilar therapy and potential savings - experience from Slovenia

In Belgrade, June 13, 2018. held a round table entitled "Safe transition to biosimilar therapy and potential savings - experience from Slovenia". At this meeting were experts from gastroenterology from Serbia and Slovenia (Prof.dr Dino Tarabar

In Belgrade, June 13, 2018. held a round table entitled "Safe transition to biosimilar therapy and potential savings - experience from Slovenia". At this meeting were experts from gastroenterology from Serbia and Slovenia (Prof.dr Dino Tarabar - Clinic for Gastroenterology and Hepatology of the VMA (Military Medical Academy), Prof. Dr. Dragomir Damjanov - Clinic for Gastroenterology and Hepatology of the Clinical Center of Vojvodina, Dr. Olgica Latinović Bošnjak - Clinic for Gastroenterology and hepatology of the Clinical Center of Vojvodina, Prof. Dr Borut Štabuc - Clinic for gastroenterology at the University Medical Center Ljubljana, Dr. Gregor Novak - Gastroenterology Clinic of the University Medical Center Ljubljana), as well as representatives of the Republic Health Fund and the Association of Illnesses UKUKS and ORS.
 
Biosimilars have been used in IBD therapy in Slovenia since 2015. In 2017, as many as 86% of these patients were on biosimilar therapy. Thanks to biosimilar, Slovenia saved € 2.5 million in 3 years, without compromising the quality of patients' treatment.